Glycoprotein 41 (gp41) – Pipeline Review, H2 2016

Global Markets Direct’s, ‘Glycoprotein 41 (gp41) – Pipeline Review, H2 2016’, provides in depth analysis on Glycoprotein 41 (gp41) targeted pipeline therapeutics.

The report provides comprehensive information on the Glycoprotein 41 (gp41), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Glycoprotein 41 (gp41) targeted therapeutics development and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note:

*Certain sections in the report may be removed or altered based on the availability and relevance of data.

*Updated report will be delivered in 48 hours of order confirmation.

Scope

The report provides a snapshot of the global therapeutic landscape for Glycoprotein 41 (gp41)

The report reviews Glycoprotein 41 (gp41) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in Glycoprotein 41 (gp41) targeted therapeutics and enlists all their major and minor projects

The report assesses Glycoprotein 41 (gp41) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news and deals related to Glycoprotein 41 (gp41) targeted therapeutics

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand the targeted therapy areas and indications for Glycoprotein 41 (gp41)

Identify the use of drugs for target identification and drug repurposing

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Glycoprotein 41 (gp41) development landscape

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Companies mentioned

Amunix Operating Inc.

BioClonetics Immunotherapeutics, Inc.

ConjuChem, LLC

Frontier Biotechnologies Co., Ltd

InnaVirVax SA

Longevity Biotech, Inc

Mymetics Corporation

Navigen Pharmaceuticals, Inc.

Osel, Inc.

Pharis Biotec GmbH

Table of Contents

Table of Contents

Table of Contents 2

List of Tables 5

List of Figures 6

Introduction 7

Global Markets Direct Report Coverage 7

Glycoprotein 41 (gp41) Overview 8

Therapeutics Development 9

Glycoprotein 41 (gp41) - Products under Development by Stage of Development 9

Glycoprotein 41 (gp41) - Products under Development by Therapy Area 10

Glycoprotein 41 (gp41) - Products under Development by Indication 11

Glycoprotein 41 (gp41) - Pipeline Products Glance 12

Late Stage Products 12

Early Stage Products 13

Glycoprotein 41 (gp41) - Products under Development by Companies 14

Glycoprotein 41 (gp41) - Products under Development by Universities/Institutes 16

Glycoprotein 41 (gp41) - Therapeutics Assessment 18

Assessment by Monotherapy/Combination Products 18

Assessment by Mechanism of Action 19

Assessment by Route of Administration 20

Assessment by Molecule Type 22

Glycoprotein 41 (gp41) - Companies Involved in Therapeutics Development 24

Amunix Operating Inc. 24

BioClonetics Immunotherapeutics, Inc. 25

ConjuChem, LLC 26

Frontier Biotechnologies Co., Ltd 27

InnaVirVax SA 28

Longevity Biotech, Inc 29

Mymetics Corporation 30

Navigen Pharmaceuticals, Inc. 31

Osel, Inc. 32

Pharis Biotec GmbH 33

Glycoprotein 41 (gp41) - Drug Profiles 34

Biologic for Infectious Disease - Drug Profile 34

Product Description 34

Mechanism Of Action 34

R&D Progress 34

CLONE-3 - Drug Profile 36

Product Description 36

Mechanism Of Action 36

R&D Progress 36

CPT-31 - Drug Profile 37

Product Description 37

Mechanism Of Action 37

R&D Progress 37

DAC-HIV - Drug Profile 38

Product Description 38

Mechanism Of Action 38

R&D Progress 38

DS-007 - Drug Profile 39

Product Description 39

Mechanism Of Action 39

R&D Progress 39

Enfuvirtide-XTEN - Drug Profile 40

Product Description 40

Mechanism Of Action 40

R&D Progress 40

FB-006M - Drug Profile 42

Product Description 42

Mechanism Of Action 42

R&D Progress 42

HIV-1 vaccine - Drug Profile 43

Product Description 43

Mechanism Of Action 43

R&D Progress 43

LBT-5001 - Drug Profile 44

Product Description 44

Mechanism Of Action 44

R&D Progress 44

Monoclonal Antibodies to Target GP120 and GP41 for HIV - Drug Profile 45

Product Description 45

Mechanism Of Action 45

R&D Progress 45

MYMV-101 - Drug Profile 46

Product Description 46

Mechanism Of Action 46

R&D Progress 46

MYMV-201 - Drug Profile 49

Product Description 49

Mechanism Of Action 49

R&D Progress 49

Recombinant Peptides for HIV-1 - Drug Profile 50

Product Description 50

Mechanism Of Action 50

R&D Progress 50

Small Molecules to Target GP120 and Gp41 for HIV-1 Infections - Drug Profile 51

Product Description 51

Mechanism Of Action 51

R&D Progress 51

STOP-3S - Drug Profile 52

Product Description 52

Mechanism Of Action 52

R&D Progress 52

Synthetic Peptide to Target gp41 for HIV Infection - Drug Profile 53

Product Description 53

Mechanism Of Action 53

R&D Progress 53

Synthetic Peptides to Inhibit GP120, GP41, Tat, Integrase and Protease for HIV-1 Infection - Drug Profile 54

Product Description 54

Mechanism Of Action 54

R&D Progress 54

VAC-02 - Drug Profile 55

Product Description 55

Mechanism Of Action 55

R&D Progress 55

VAC-3S - Drug Profile 56

Product Description 56

Mechanism Of Action 56

R&D Progress 56

VIR-576 - Drug Profile 58

Product Description 58

Mechanism Of Action 58

R&D Progress 58

Glycoprotein 41 (gp41) - Dormant Projects 59

Glycoprotein 41 (gp41) - Featured News & Press Releases 60

Sep 19, 2016: Mymetics and Texas Biomedical Research Institute Continue Collaboration on HIV Vaccine Development 60

Jun 06, 2016: Frontier Biotech Long-acting HIV-1 Fusion Inhibitor Albuvirtide Meets 48-Week Primary Objective: Interim Results of a Phase 3 Trial 61

Apr 11, 2016: Mymetics' HIV vaccine candidate confirms promise in preclinical study with Texas Biomed 61

Jul 30, 2015: Encouraging results of the first clinical study of the VAC-3S vaccine against HIV, for which DIAXONHIT develops a companion diagnostic 63

Apr 30, 2015: Texas Biomed receives NIH grant to study papillomavirus-based AIDS vaccine 64

Oct 28, 2014: Amunix and PolyPeptide Enter Into Partnership to Produce XTEN Peptide Conjugates for Evaluation by Third Parties for Pharmaceutical Therapeutics 65

Jul 23, 2014: Amunix and PolyPeptide Publish Multivalent Antiviral XTEN-Peptide Conjugates in vivo Studies in American Chemical Society's Journal "Bioconjugate Chemistry" 65

Dec 01, 2013: InnaVirVax Initiates Phase 2 Clinical Trial Evaluating VAC-3S, A Therapeutic Vaccine Used in Combination With Standard Antiretroviral Therapy in Treatment of HIV-Infection 66

Mar 05, 2013: InnaVirVax Presents Results From Phase I/IIa Clinical Study Of VAC-3S At CROI 2013 67

Feb 21, 2013: Mymetics Announces Publication Of Positive Phase I Study Results Of HIV-1 Vaccine In PLOS ONE 67

Nov 30, 2012: InnaVirVax's HIV Vaccine VAC-3S Achieves Primary End Point In Phase I/IIa Study 68

Jun 18, 2012: InnaVirVax Files New European Patent Application For VAC-3S Immunotherapy 69

Mar 05, 2012: InnaVirVax Initiates Phase I/IIa Clinical Trial Of VAC-3S For Treatment Of HIV Infections 69

Oct 13, 2011: InnaVirVax Obtains Authorization From French Drug Agency To Start Phase I/IIa Study Of VAC-3S 70

Jun 22, 2011: InnaVirVax Announces Positive Preclinical Results Of VAC-3S For Treatment Of HIV Infections 71

Appendix 72

Methodology 72

Coverage 72

Secondary Research 72

Primary Research 72

Expert Panel Validation 72

Contact Us 72

Disclaimer 73

List of Tables

List of Tables

Number of Products under Development for, H2 2016 9

Number of Products under Development by Therapy Area, H2 2016 10

Number of Products under Development by Indication, H2 2016 11

Comparative Analysis by Late Stage Development, H2 2016 12

Comparative Analysis by Early Stage Products, H2 2016 13

Number of Products under Development by Companies, H2 2016 14

Products under Development by Companies, H2 2016 15

Number of Products under Investigation by Universities/Institutes, H2 2016 16

Products under Investigation by Universities/Institutes, H2 2016 17

Assessment by Monotherapy/Combination Products, H2 2016 18

Number of Products by Stage and Mechanism of Action, H2 2016 19

Number of Products by Stage and Route of Administration, H2 2016 21

Number of Products by Stage and Molecule Type, H2 2016 23

Pipeline by Amunix Operating Inc., H2 2016 24

Pipeline by BioClonetics Immunotherapeutics, Inc., H2 2016 25

Pipeline by ConjuChem, LLC, H2 2016 26

Pipeline by Frontier Biotechnologies Co., Ltd, H2 2016 27

Pipeline by InnaVirVax SA, H2 2016 28

Pipeline by Longevity Biotech, Inc, H2 2016 29

Pipeline by Mymetics Corporation, H2 2016 30

Pipeline by Navigen Pharmaceuticals, Inc., H2 2016 31

Pipeline by Osel, Inc., H2 2016 32

Pipeline by Pharis Biotec GmbH, H2 2016 33

Dormant Projects, H2 2016 59

List of Figures

List of Figures

Number of Products under Development for, H2 2016 9

Comparative Analysis by Late Stage Development, H2 2016 12

Comparative Analysis by Early Stage Products, H2 2016 13

Assessment by Monotherapy/Combination Products, H2 2016 18

Number of Products by Stage and Mechanism of Actions, H2 2016 19

Number of Products by Routes of Administration, H2 2016 20

Number of Products by Stage and Routes of Administration, H2 2016 20

Number of Products by Molecule Types, H2 2016 22

Number of Products by Stage and Molecule Type, H2 2016 22

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports